| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The primary targets of 3-Oxo-C14-AHL are LuxR-type quorum sensing receptors in bacteria. These receptors are transcription factors that, upon binding to AHL molecules, activate or repress the expression of target genes involved in virulence, biofilm formation, bioluminescence, and other collective behaviors. Different bacterial species produce and respond to specific AHL molecules, with the acyl chain length and substitution pattern determining receptor specificity. 3-Oxo-C14-AHL is a long-chain AHL with specific signaling properties.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that 3-Oxo-C14-AHL activates LuxR-type quorum sensing receptors in a concentration-dependent manner. The compound's activity can be assessed using reporter gene assays where the AHL-responsive promoter is linked to a reporter such as luciferase or β-galactosidase. The compound shows specific activity for certain LuxR homologs, with the 3-oxo substitution and 14-carbon chain length providing distinct signaling properties compared to other AHLs. Structure-activity relationship studies have characterized the importance of the acyl chain for receptor binding and activation.
|
| ln Vivo |
In vivo studies in bacterial cultures and animal models have shown that 3-Oxo-C14-AHL regulates quorum sensing-dependent phenotypes such as virulence factor production and biofilm formation. In pathogenic bacteria, AHL-mediated quorum sensing controls the expression of toxins and other virulence factors. The compound can be used to study the role of quorum sensing in bacterial pathogenesis and to screen for quorum sensing inhibitors. In vivo studies in infection models have demonstrated the importance of AHL signaling in bacterial virulence.
|
| Enzyme Assay |
Non-cellular assays for 3-Oxo-C14-AHL typically involve measuring its binding affinity to LuxR-type receptors using techniques such as isothermal titration calorimetry (ITC) or surface plasmon resonance (SPR). These assays determine the dissociation constant (KD) and binding kinetics. Competition binding assays may be used to assess the relative affinity of different AHL analogs. These cell-free systems allow for precise characterization of the compound's receptor binding properties.
|
| Cell Assay |
Cellular assays for 3-Oxo-C14-AHL utilize bacterial reporter strains containing AHL-responsive promoters fused to reporter genes. The compound is added to bacterial cultures, and reporter activity is measured to assess quorum sensing activation. Dose-response curves are generated to determine EC50 values. These assays are used to characterize the signaling properties of AHLs and to screen for quorum sensing agonists and antagonists.
|
| Animal Protocol |
In vivo animal experiments for 3-Oxo-C14-AHL typically involve infection models using pathogenic bacteria. The compound may be administered to study its effects on bacterial virulence and pathogenesis. Alternatively, quorum sensing inhibitors may be tested in the presence of AHLs to assess their efficacy in reducing bacterial virulence in vivo. These studies provide insights into the role of quorum sensing in infection and the potential of quorum sensing-targeted therapies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 3-Oxo-C14-AHL are not well-characterized, as the compound is primarily used as a research tool in microbiology rather than as a therapeutic agent. As a small lipophilic molecule, it may have limited aqueous solubility. The compound is typically dissolved in organic solvents such as DMSO or ethanol for experimental use. Its stability in biological media and its distribution in vivo depend on its physicochemical properties and the specific experimental conditions.
|
| Toxicity/Toxicokinetics |
Toxicological data for 3-Oxo-C14-AHL are limited, as the compound is used as a research reagent rather than a therapeutic agent. As a bacterial signaling molecule, it is not intended for human use. Standard laboratory safety precautions should be followed when handling the compound. The compound's toxicity profile in mammalian systems has not been extensively characterized.
|
| References |
|
| Additional Infomation |
Other information includes the compound's role as a quorum sensing autoinducer in Gram-negative bacteria. It is a N-acyl homoserine lactone with a 14-carbon acyl chain and a 3-oxo substitution. The compound is used in microbiology research to study bacterial cell-cell communication, virulence regulation, and biofilm formation. It is also used to screen for quorum sensing inhibitors as potential anti-infective agents. The compound is available as a research reagent from chemical suppliers.
|
| Molecular Formula |
C18H31NO4
|
|---|---|
| Molecular Weight |
325.44
|
| Exact Mass |
325.225
|
| CAS # |
503610-29-5
|
| PubChem CID |
11688418
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.689
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
23
|
| Complexity |
381
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCC(=O)CC(=O)NC1CCOC1=O
|
| InChi Key |
YQFJJDSGBAAUPW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H31NO4/c1-2-3-4-5-6-7-8-9-10-11-15(20)14-17(21)19-16-12-13-23-18(16)22/h16H,2-14H2,1H3,(H,19,21)
|
| Chemical Name |
3-oxo-N-(2-oxooxolan-3-yl)tetradecanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (307.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.68 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.68 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0728 mL | 15.3638 mL | 30.7276 mL | |
| 5 mM | 0.6146 mL | 3.0728 mL | 6.1455 mL | |
| 10 mM | 0.3073 mL | 1.5364 mL | 3.0728 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
